A Phase 4 interventional study of Ezetimibe and simvastatin in Cardiovascular Disorder, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Collecting local data, safety and experience trial.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 280 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
Drug: Ezetimibe · Drug: simvastatin
arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Drug: simvastatin
Ezetimibe 10 mg daily for 42 days.
Also known as: Ezetrol®, Zetia®, MK0653
simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Also known as: Zocor®, MK0733
LDL levels
Time frame: 42 Days
Safety measures
Time frame: 42 days
Total cholesterol levels.
Time frame: 42 Days
No study locations are listed for this record.
Ran from Feb 2005 to primary completion in Feb 2005, 0 months.
Of 113 phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's 0 months is below that.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ezetimibe